Human Genome Sciences has named Craig C. Parker its senior vice president, strategy and corporate development. He will report directly to H. Thomas Watkins, president and chief executive officer, and will serve as a member of the management committee.

Parker was most recently CEO and co-founder of Vega Therapeutics, a biotechnology start-up focused on inflammation, obesity and insulin resistance. He was formerly senior vice president of corporate development and finance and chief financial officer of Proteolix which was acquired by Onyx Pharmaceuticals.

“Partnering with our commercial, finance and R&D teams, Craig will lead future development of our global business strategy as well as the evaluation and execution of business development opportunities,” said Mr. Watkins.